Bipolar Disorder and Alcohol Use Disorder: A Review
Bipolar Disorders (MA Frye, Section Editor)
First Online: 15 September 2012 DOI:
10.1007/s11920-012-0320-9 Cite this article as: Farren, C.K., Hill, K.P. & Weiss, R.D. Curr Psychiatry Rep (2012) 14: 659. doi:10.1007/s11920-012-0320-9 Abstract
Bipolar disorder and alcohol use disorder represent a significant comorbid population, which is significantly worse than either diagnosis alone in presentation, duration, co-morbidity, cost, suicide rate, and poor response to treatment. They share some common characteristics in relation to genetic background, neuroimaging findings, and some biochemical findings. They can be treated with separate care, or ideally some form of integrated care. There are a number of pharmacotherapy trials, and psychotherapy trials that can aid program development. Post-treatment prognosis can be influenced by a number of factors including early abstinence, baseline low anxiety, engagement with an aftercare program and female gender. The future development of novel therapies relies upon increased psychiatric and medical awareness of the co-morbidity, and further research into novel therapies for the comorbid group.
Keywords Alcohol use disorder AUD Bipolar disorder BD Comorbidity Genetics Neuroimaging Treatment Integrated Psychotherapy Pharmacotherapy Treatment program FIRESIDE Integrated group therapy Psychiatry References Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Regier DA, Farmer ME, Rae DS, Locke BZ, Keith SJ, Judd LL. Comorbidity of mental disorders with alcohol and other drug abuse. Results from the Epidemiological Catchement Area (ECA) Study. JAMA. 1990;264:2511–8.
Hasin DS, Stinson FS, Ogburn E, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV alcohol abuse and dependence in the United States. Arch Gen Psychiatry. 2007;64:830–8425.
Kessler RC, Crum RM, Warner LA, Nelson CB, Schulenberg J, Anthony JC. Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch Gen Psychiatry. 2007;54:313–21.
Cardoso BM, Kauer SM, Dias VV, Andreazza AC, Cereser KM, Kapczinski F. The impact of co-morbid alcohol use in bipolar patients. Alcohol. 2008;42:451–7.
Frye MA, Salloum IM. Bipolar disorder and co-morbid alcoholism: prevalence rate and treatment considerations. Bipolar Disord. 2006;8:677–85.
Feinman JA, Dunner DL. The effect of alcohol abuse on the course of bipolar affective disorder. J Affect Disord. 1996;37:43–9.
Salloum IM, Cornelius JR, Mezzich JE, Kirisci L. Impact of concurrent alcohol misuse on symptom presentation of acute mania at initial evaluation. Bipolar Disord. 2002;60:418–21.
Strakowski SM, DelBello N, Fleck DE, Adler CM, Anthenelli RM, Keck PE, et al. Effect of co-occurring alcohol abuse on the course of bipolar disorder following a first hospitalization for mania. Arch Gen Psychiatry. 2005;62:851–8.
Van Zaane J, Van Der Brink W, Draisma S, Smit JH, Nolen WA. The effect of moderate and excessive alcohol use on the course and outcome of patients with bipolar disorder. J Clin Psychiatry. 2010;71:885–93.
Maier W, Merikangas K. Co-occurrence and cotransmission of affective disorders and alcoholism in families. Br J Psychiatry. 1996;30(Suppl):93–100.
Swann AC, Pazzaglia P, Nicholls A, Dougherty DM, Moeller FG. Impulsivity and phase of illness in bipolar disorder. J Affect Disord. 2003;73:105–11.
Frye MA, Altschuler LL, McElroy SL, Suppes T, Keck PE, Denicoff K, et al. Gender differences in prevalence, risk, and clinical correlates of alcoholism comorbidity in bipolar disorder. Am J Psychiatry. 2003;160:883–9.
Craddock N, Sklar P. Genetics of bipolar disorder: successful start to a long journey. Trends Genet. 2009;25:99–105.
Farmer A, Elkin A, McGuffin P. The genetics of bipolar disorder. Curr Opin Psychiatry. 2007;20:8–12.
Serretti A, Mandelli L. The genetics of bipolar disorder: genome ‘hot regions’, genes, new potential candidates and future directions. Mol Psychiatry. 2008;13:742–71.
Mayfield RD, Harris RA, Schuckit MA. Genetic factors influencing alcohol dependence. Br J Pharmacol. 2008;154:275–87.
Kendler KS, Schmitt E, Aggen SH, Prescott CA. Genetic and environmental influences of alcohol, caffeine, cannabis, and nicotine use from early adolescence to middle adulthood. Arch Gen Psychiatry. 2008;65:674–82.
Smyth BP, Kelly A, Cox G. Decline in age of drinking onset in Ireland, gender and per capita alcohol consumption. Alcohol Alcohol. 2011;46:478–84.
Dick DM, Jones K, Saccone N, Hinricks A, Wang JC, Goate A, et al. Endophenotypes successfully lead to gene identification: results from the collaborative study on the genetics of alcoholism. Behav Genet. 2006;36:112–26.
Strat YL, Ramoz N, Schumann G, Gorwood P. Molecular genetics of alcohol dependence and related endophenotypes. Curr Genomics. 2008;9:444–51.
Schuckit MA. Low level of response to alcohol as a predictor of future alcoholism. Am J Psychiatry. 1994;151:184–9.
Garbutt JC, Osborne M, Gallop R, Barkenbus J, Grace K, Cody M, et al. Sweet liking phenotype, alcohol craving, and response to naltrexone treatment in alcohol dependence. Alcohol Alcohol. 2009;44:293–300.
Cloninger CR. Neurogenic adaptive mechanisms in alcoholism. Science. 1987;236:410–6.
Irwin M, Schuckit M, Smith TL. Clinical importance of age of onset in Type 1 and Type 2 primary alcoholics. Arch Gen Psychiatry. 1990;47:320–4.
Babor TF, Hofmann M, DelBoca FK, Hesselbrock V, Meyer RE, Dolinsky ZS, Rounsaville B. Types of alcoholics I. Evidence for an empirically derived typology based on indicators of vulnerability and severity. Arch Gen Psychiatry. 1992;49:599–608.
Kendler KS, Heath AC, Neale MC, Kessler RC, Eaves LJ. A population-based twin study of alcoholism in women. JAMA. 1992;268:1877–82.
Yasseen B, Kennedy JL, Zawertailo LA, Busto UE. Comorbidity between bipolar disorder and alcohol use disorder. Association of dopamine and serotonin gene polymorphisms. Psychiatry Res. 2010;176:30–3.
Chang K, Adelman NE, Dienes K, Simeonova DI, Menon V, Reiss A. Anomolous prefrontal-subcortical activation in familial pediatric bipolar disorder. Arch Gen Psychiatry. 2004;61:781–92.
Strakowski SM, DelBello MP, Adler CM. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry. 2005;10:105–16.
Farren CK, Buchsbaum M, Hazlett E, Banks A. FDG-PET scanning in newly abstinent alcoholics: Fronto-striatal abnormalities. Alcohol Clin Exp Res. 2001;25(Suppl):78A.
Myrick H, Aonton RF, Li X, Henderson S, Randall PK, Voronin K. Effects of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people. Arch Gen Psychiatry. 2008;65:466–75.
Volkow ND, Wang G-J, Telang F, Fowler JS, Logan J, Jayne M, et al. Profound decreases in dopamine release in striatum in detoxified alcoholics: possible orbitofrontal involvement. J Neurosci. 2007;27:12700–6.
Lam DH, Watkins ER, Hayward P, Bright J, Wright K, Kerr N, et al. A randomized controlled study of cognitive therapy for relapse prevention for bipolar affective disorder: outcome of the first year. Arch Gen Psychiatry. 2003;60:145–52.
Miklowitz DJ, George EL, Richards JA, Simoneau TL, Suddath RL. A randomized study of family-focused psychoeducation and pharmacotherapy in the outpatient management of bipolar disorder. Arch Gen Psychiatry. 2003;60:904–12.
Frank E, Kupfer DJ, Thase ME, Mallinger AG, Swartz HA, Fagiolini AM, et al. Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorder. Arch Gen Psychiatry. 2005;62:996–1004.
Colom F, Vieta E, Martinez-Aran A, Reinares M, Goikolea JM, Benabarre A, et al. A randomized trial on the efficacy of group psychoeducation in the prophylaxis of recurrences in bipolar patients whose disease is in remission. Arch Gen Psychiatry. 2003;60:402–7.
Project MATCH Research Group. Matching alcoholism treatments to client heterogeneity: project MATCH posttreatment drinking outcomes. J Stud Alcohol. 1997;58:7–29.
Anton RF, O’Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence. The COMBINE study: a randomized controlled trial. JAMA. 2006;295:2003–17.
Hien DA, Cohen LR, Miele GM, Litt LC, Capstick C. Promising treatments for women with comorbid PTSD and substance use disorders. Am J Psychiatry. 2004;161:1426–32.
Ziedonis DM, Smelson D, Rosenthal RN, Batki SL, Green AI, Henry RJ, et al. Improving the care of individuals with schizophrenia and substance use disorders: consensus recommendations. J Psychiatr Pract. 2005;11:315–37.
Bellack AS, Bennett ME, Gearon JS, Brown CH, Yang Y. A randomized clinical trial of a new brehavioral treatment for drug abuse in people with severe and persistent mental illness. Arch Gen Psychiatry. 2006;63(4):426–32.
•• Farren CK, McElroy S. Predictive factors for relapse after an integrated inpatient treatment program for unipolar depressed and bipolar alcoholics. Alcohol Alcohol. 2010;45:527–33.
This research assesses the predictive factors that have been identified that predict response to an integrated inpatient treatment programme for BD and AUD
Farren CK, McElroy S. Treatment response of bipolar and unipolar alcoholics to an inpatient dual diagnosis program. J Affect Disord. 2008;106:265–72.
Farren CK, Snee L, McElroy S. Gender differences at 2-year follow-up of treated bipolar and depressed alcoholics. J Stud Alcohol Drugs. 2011;72:872–80.
Weiss RD, Griffin ML, Greenfield SF, Najavits LM, Wyner D, Soto JA, Hennen JA. Group therapy for patients with bipolar disorder and substance dependence: results of a pilot study. J Clin Psychiatry. 2006;61:361–7.
Weiss RD, Griffin ML, Kolodziej ME, Greenfield SF, Najavits LM, Daley DC, Doreau HR, Hennen JA. A randomized trial of integrated group therapy versus group drug counseling for patients with bipolar disorder and substance dependence. Am J Psychiatry. 2007;164:100–7.
•• Weiss RD, Griffin ML, Jaffee WB, Bender RE, Graff FS, Gallop RJ, Fitzmaurice GM. A “community-friendly” version of integrated group therapy for patients with bipolar disorder and substance dependence: a randomized controlled trial. Drug Alcohol Depend. 2009;104:212–9.
This paper examines the effectiveness of the novel therapy IGT in the treatment of comorbid BD and substance dependence in the real world setting of community treatment programmes, applicable outside research centres.
Weiss RD, Connery HS. Integrated group therapy for bipolar disorder and substance abuse. New York: Guilford Press; 2011.
Weiss RD, Kolodziej ME, Najavits LM, Greenfield SF, Fucito LM. Utilization of psychosocial treatments by patients diagnosed with bipolar disorder and substance dependence. Am J Addict. 2000;9:314–20.
Daley DC, Mercer D, Carpenter G. Group drug counseling for cocaine dependence: therapy manuals for drug addition. United States Department of Health and Human Services, 2002.
Crits-Christoph P, Siqueland L, Blaine J, Frank A, Luborsky L, Onken L, et al. Psychosocial treatments for cocaine dependence: results of the National Institute on Drug Abuse Collaborative Cocaine Treatment Study. Arch Gen Psychiatry. 1999;56:493–502.
Bowden CL, Brugger AM, Swann AC, Calabrese JR, Janicak PG, Petty F, et al. Efficacy of dibalproex vs, lithium and placebo in the treatment of mania [published erratum appears in JAMA]. JAMA. 1994;271:918–24.
Hillborn M, Tokola R, Kuusela V, Karkkainen P, Kalli-Lemma L, Pilke A, Kaste M. Prevention of alcohol withdrawal seizures with carbamazepine and valproic acid. Alcohol. 1989;6:223–6.
Hammer BA, Brady KT. Valproate treatment of alcohol withdrawal and mania. Am J Psychiatry. 1996;153:1232.
Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, et al. Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet. 2003;361:1677–85.
Brady KT, Myrick H, Henderson S, Coffey SF. The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. 2002;67:323–30.
Salloum IM, Cornelius JR, Daley DC, Kirisci L, Himmeloch JM, Thase ME, et al. Efficacy of valproate maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch Gen Psychiatry. 2005;62:37–45.
Kemp DE, Gao K, Ganocy SJ, Elhaj O, Bilali SR, Conroy C, et al. A 6-month double-blind, maintenance trial of lithium monotherapy versus the combination of lithium and divalproex for rapid-cycling bipolar disorder and co-occurring substance abuse or dependence. J Clin Psychiatry. 2009;70:113–21.
Drake RE, Xie H, McHugo GJ, Green AI. The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull. 2000;26:441–9.
Littrell KH, Petty RG, Hilligoss NM, Peabody CD, Johnson CG. Olanzapine treatment for patients with schizophrenia and substance abuse. J Subst Abus Treat. 2001;21:217–21.
Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000;20:94–8.
Kampman KM, Pettinati HM, Lynch KG, Whittingham T, Macfadden W, Dackis C, et al. A double-blind, placebo-controlled pilot trial of quetiapine for the treatment of type A and type B alcoholism. J Clin Psychopharmacol. 2007;27:344–51.
Brown ES, Garza M, Carmody TJ. A randomized, double-blind, placebo-controlled add-on trial of quetiapine in outpatients with bipolar disorder and alcohol use disorders. J Clin Psychiatry. 2008;69:701–5.
Stedman M, Pettinati HM, Brown ES, Kotz M, Calabrese JR, Raines S. A double-blind, placebo-controlled study with quetiapine as adjunct therapy with lithium of divalproex in bipolar I patients with coexisting alcohol dependence. Alcohol Clin Exp Res. 2010;34:1822–31.
Martinotti G, Andreoli S, Di Nicola M, Di Giannantonio M. Quetiapine decreases alcohol consumption, craving, and psychiatric symptoms in dually diagnosed alcoholics. Hum Psychopharmacol Clin Exp. 2008;23:417–24.
Kranzler HR, Van Kirk J. Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol Clin Exp Res. 2001;25:1335–41.
Croop RS, Faulkner EB, Labriola DF. The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group. Arch Gen Psychiatry. 1997;54:1130–5.
Salloum I, Cornelius J, Thase M, Daley D, Kirisci L, Spotts C. Naltrexone utility in depressed alcoholics. Psychopharmacology. 1998;34:111–5.
Maxwell S, Shinderman MS. Use of naltrexone in the treatment of alcohol use disorders in patients with concomitant major mental illness. J Addict Disord. 2000;19:61–9.
Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E. Naltrexone for alcohol dependence: a randomized controlled trial [comment]. Addiction. 2001;96:1565–73.
Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biol Psychiatry. 2005;57:1128–37.
Brown ES, Beard L, Dobbs L, Rush AJ. Naltrexone in patients with bipolar disorder and alcohol dependence. Depress Anxiety. 2006;23:492–5.
• Brown ES, Carmody TJ, Schmitz JM, Caetano R, Adinoff B, Swann AC, Rush AJ. A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence. Alcohol Clin Exp Res. 2009;33:1863–9.
This study examines a study response to the anticraving medication naltrexone in BD and AUD in an outpatient setting. Although essentially a negative study, it is an important milestone in pharmacotherapy trials for this comorbidity
Tolliver B, McRae A, Sonne SC, Brady KT. Safety and tolerability of acamprosate in alcohol-dependent individuals with bipolar disorder. An open-label pilot study. Addict Disord Treat. 2009;8:33–8.
Tolliver BK, DeSantis SM, Brown DG, Prisciandaro JJ, Brady KT. A randomized, double-blind, placebo-controlled trial of acamprosate in alcohol-dependent individuals with bipolar disorder: a preliminary report. Bipolar Disord. 2012;14:54–63.
PubMed CrossRef Copyright information
© Springer Science+Business Media, LLC 2012